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Summary Thirty-four patients with progressive low grade non-Hodgkin's lymphoma were treated with 1 lg
oral alfacalcidol daily. Complete response was seen in four patients and a partial response in four patients
with an overall response rate of 24%. Median duration of response was 14 months. Disease stabilised in ten
other patients (29%) and 16 patients (47%) had tumour progression. In the sub-group of patients with
follicular, small-cleaved cell lymphoma the overall response to treatment was 29%. Apart from one patient
who had a mild transitory elevation of serum calcium there was no recorded toxicity from alfacidol. These
results indicate that alfacalcidol has significant antitumour activity in patients with low grade non-Hodgkin's
lymphoma of the follicular, small-cleaved cell type.
The use of cytotoxic drugs in low grade non-Hodgkin's
lymphoma is in general reserved for the treatment of sympto-
matic disease. This policy has evolved because although these
tumours respond to chemotherapy, almost all patients relapse
after achieving complete remission (Schein et al., 1975) prob-
ably because of residual disease in the bone marrow (Lee et
al., 1987). Clearly, new approaches to the management of
this tumour are required. In this regard, we have previously
reported a pilot study of ten patients with low grade non-
Hodgkin's lymphoma who were treated with oral alfacalcidol
1 fig daily (Cunningham et al., 1985). Three of the ten
patients experienced objective tumour regression and the tox-
icity related to alfacalcidol was minimal. We have now
extended the study to include 36 patients and in this paper
report the response and toxicity data.
Patients and methods
Thirty-six patients (25 female and 11 male) with low grade
lyphoma (28 follicular small-cleaved cell and eight small
lymphocytic) (International Working Classification - IWF)
have entered this prospective study since 1984. Nineteen
patients had not received prior chemotherapy for their lym-
phoma. Seventeen patients had required previous chemo-
therapy for their lymphoma. The mean age was 61 years. All
patients had shown disease progression for at least 8 weeks
before starting treatment and had the following pre-
treatment evaluation: clinical measurement of nodes and
organomegaly, baseline haemoglobin, total and differential
white cell count, platelet count, erythrocyte sedimentation
rate, bilirubin, aspartate and alanine transaminase, calcium,
inorganic phosphate, alkaline phosphatase and a chest
radiograph. CT scan of the chest and abdomen and
abdominal ultrasound were performed, as appropriate.
Patients were subsequently reviewed every 4 weeks when
clinical examination and the pre-treatment investigations
were repeated.
Alfacalcidol, I tLg daily, orally was given for a minimum of
8 weeks. If tumour regression occurred or disease remained
stable, treatment was continued for 1 year. Alfacalcidol was
discontinued in the presence of progression of lymphoma or
treatment related toxicity. Response was assessed using the
standard criteria of the World Health Organisation (Miller et
al., 1981). The study was approved by the Ethics Committee
of Glasgow Royal Infirmary. All patients gave verbal in-
formed consent for inclusion in the study.
Results
Data from 34 patients have been analysed. Two patients were
excluded; one due to poor compliance with alfacalcidol, the
other because rebiopsy of a lymph node taken prior to
commencing alfacalcidol revealed transformation to diffuse
large cell lymphoma. Four patients with follicular small-
cleaved cell lymphoma achieved complete remission with re-
sponse durations of 36, 14, 12 and 10 months respectively
(Figure 1). The response to therapy in these patients was
attained between 6-8 weeks after starting treatment. Three
of these patients had not received any chemotherapy in the
past. One of these responding patients developed asympto-
matic hypercalcaemia at 20 weeks; alfacalcidol was stopped
and hypercalcaemia resolved over 6 weeks. This patient has
remained in remission to date. Four patients with follicular
small-cleaved cell lymphoma achieved a partial remission. On
relapse with progressive disease, a response of 12, 14 and 16
months' duration was attained with alfacalcidol. The fourth
patient was previously untreated and had a partial remission
lasting 10 months. On relapse, he was given CHOP chemo-
therapy, but died from a rapidly progressive lymphoma. At
autopsy, histology indicated transformation to a diffuse large
cell lymphoma. The disease in ten further patients stabilised
on alfacalcidol for a period of 4-24 months (median 9
months). Nine of these had follicular small-cleaved cell histo-
logies and one small lymphocytic lymphoma. In each, on
further progression of disease, alfacalcidol was stopped if it
had not already been discontinued after 1 year of treatment,
and appropriate chemotherapy given. In 16 patients there
was no response to alfcalcidol. All of these patients required
combination chemotherapy for progressive disease. Five of
these patients have since died of progressive lymphoma.
Three patients, who had previously responded to alfacalcidol
and progressed after treatment was stopped, responded again
to alfacalcidol in an identical way.
Apart from the patient who had a transitory elevation of
serum calcium (2-8 mmol 1-') there were no side-effects
recorded due to alfacalcidol.
Discussion
This study demonstrated that alfacalcidol has anti-tumour
activity in a significant proportion of patients with follicular
small-cleaved cell lymphoma, the most common histological
sub-type of low grade non-Hodgkin's lymphoma. In this
group, treatment with alfacalcidol resulted in tumour regres-
sion or disease stabilisation in over 50% of patients. Such
therapy was delivered with minimal toxicity which is import-
ant because of the favourable natural history of this tumour
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Figure I Shows the complete regression of para-aortic lympha-
denopathy which occurred 12 weeks after beginning treatment
with alfacalcidol.
and because many of the patients are in the elderly age
group Moreover, on relapse after successful treatment with
alfacalcidol, all but one patient responded to chemotherapy,
therefore, it appears that this therapeutic approach does not
prejudice the subsequent response to chemotherapy. Hence, it
could be argued that alfacalcidol should be used as a primary
treatment for patients with low grade lymphoma. Delaying
the introduction of chemotherapy may reduce the risk of
acquired drug resistance in tumours which later progress in
the low grade form and in tumours which transform to high
grade lymphoma. Furthermore, the risk of long term second-
ary leukaemia is likely to be reduced if patients received
initial treatment with alfacalcidol rather than alkylating
agents which are known to be leukaemogenic.
Spontaneous regression is well recognised in low grade
lymphomas, the generally accepted figure is of the order of
5%. However, these regressions are usually fluctuant and
incomplete (Wiernik, 1976) and the median time to spon-
taneous regression is around 8 months (Horning & Rosen-
berg, 1984). The response rate of 24% in our series is con-
siderably higher and the median time to remission of 6-8
weeks, significantly faster than spontaneous regressions for
patients with progressive lymphomas. Additionally, the re-
sponses were sustained for protracted periods of time and in
some patients a second remission was induced on further
alfacalcidol therapy. All of these factors strongly support our
contention that the documented responses were not due to
spontaneous regression. Horning and Rosenberg (1984), have
reported a spontaneous remission rate of 23%, but it must be
emphasised that this group of patients was selected for quies-
cent disease (Horning & Rosenberg, 1984). In our study, all
patients had documented disease progression before begin-
ning alfacalcidol.
The mechanism by which calcitriol (1,25 dihydroxyvitamin
D3) is anti-proliferative in lymphoma remains uncertain. The
calcitriol receptor, which has a molecular weight of 52-60 kd
(Pike, 1985) is found in the nucleus of many mammalian cells
(Haussler et al., 1985) and although the receptor cannot be
found on resting B and T cells it is present on activated and
malignant lymphocytes (Provvedini et al., 1983; Cunningham
et al., 1985). Recent work from Manolagas et al. (1987)
suggests that calcitriol may have an important role in the
regulation of oncogene driven growth. This hypothesis
emerged from laboratory data showing that transfection of
NIH3T3 cells (which were calcitriol receptor negative) with
c-myc rapidly led to the expression of calcitriol receptors by
these cells. Also, calcitriol has been shown to induce
differentiation of a human lymphoma cell line (Dodd et al.,
1983) and in a promyelocytic leukaemia cell line (HL-60); in
the latter, differentiation was associated with reduced expres-
sion of cellular oncogene myc (Reitman et al., 1983). It has
also been shown that 1,25 (OH)2D3 inhibits the production of
interleukin II by T-lymphocytes and that it can suppress
proliferation of and production of immunoglobulins by nor-
mal B lymphocytes (Tsoukas et al., 1984; Lemire et al.,
1984). Moreover, there are other more rapid effects of calcit-
riol on cells, such as an increase in intracellular cGMP
(Barsony & Marx, 1988) which may be receptor independent
or related to another as yet unidentified cytoplasmic receptor.
Calcitriol receptors are found on a variety of other human
tumour cell lines including myeloma, colon cancer and breast
cancer (Colston et al., 1982; Frampton et al., 1982) and has
been shown to inhibit the growth of human melanoma (Col-
ston et al., 1981) and breast cancer (Chouvet et al., 1986) cell
lines and suppress the growth of human melanoma and colon
cancer xenografts (Eisman et al., 1987).
In this study, alfacalcidol induced tumour regression in
follicular small-cleaved cell lymphoma at a dose level which
was associated with few side-effects. However, the dose
limiting toxicity of alfacalcidol is hypercalcaemia. With the
emergence of new calcitrol analogues such as MC903, which
are potent induces of cell differentiation and yet have at least
100 times less effect on calcium mineral metabolism
(Binderup & Bram, 1988) than calcitriol the potential for this
therapeutic strategy is considerable.
We would like to thank Miss Peta Heatley for typing the manuscript.
References
BARSONEY, J. & MARX, S.J. (1988). Receptor mediated rapid action
of 1,25-dihydroxycholecalciferol: increase of intracellular cGMP
in human skin fibroblasts. Proc. Natl Acad. Sci. USA, 85, 1223.
BINDERUP, L. & BRAM, E. (1988). Effects of a novel vitamin D
analogue MC903 on cell proliferation and differentiation in vitro
and on calcium metabolism in vivo. Biochem. Pharmacol., 37, 880.
CHOUVET, C., VICARD, E., DEVONEC, M. & SAEZ, S. (1986). 1,25-
dihydroxyvitamin D3 inhibitory effect on the growth of two
human breast cancer cell lines (MCF-7, BT-20). J. Steroid.
Biochem., 24, 373.
COLSTON, K., COLSTON, J.M. & FELDMAN, D. (1981). 1,25-
dihydroxyvitamin D3 and malignant melanoma: the presence of
receptors and inhibition of cell growth in culture. Endocrinology,
108, 1083.
COLSTON, K., COLSTON, J.M., FIELDSTEEL, A.H. & FELDMAN, D.
(1982). 1,25-dihydroxyvitamin D3 receptors in human epithelial
cancer cell lines. Cancer Res., 42, 856.ALFACALCIDOL IN TREATMENT OF NON-HODGKIN'S LYMPHOMA 465
CUNNINGHAM, D., GILCHRIST, N.L., COWAN, R.A., FORREST, G.J.,
McARDLE, C.S. & SOUKOP, M. (1985). Alfacalcidol as a
modulator of growth of low grade non-Hodgkin's lymphomas.
Br. Med. J., 291, 1153.
DODD, R.C., COHEN, M.S., NEWMAN, S.L. & GREY, T.K. Vitamin D
metabolites change the phenotype of monoblastic U937 cells.
Proc. Natl Acad. Sci. USA, 80, 7538.
EISMAN, J.A., BARKLA, D.H. & TUTTON, P.J.M. (1987). Suppression
of in vivo growth of human cancer solid tumour xenografts by
1,25-dihydroxyvitamin D3. Cancer Res., 47, 21.
FRAMPTON, R.J., SUVA, L.J., EISMAN, J.A. & ? others (1982).
Presence of 1,25-dihydroxyvitamin D3 receptors in established
human cancer cell lines in culture. Cancer Res., 42, 1116.
HAUSSLER, M.R., DONALDSON, C.A., KELLY, M.A., MANGLES-
DORF, D.J., MARION, S.L. & PIKE, J.W. (1985). In Vitamin D:
Chemical, Biochemical and Clinical Update. Norman, A.W.,
Schaefer, K., Grigoleit, H.G. & VON Herrath, D. (eds). de
Gruyter: Berlin. 83.
HORNING, S.J. & ROSENBERG, S.A. (1984). The natural history of
initially untreated low grade non-Hodgkin's lymphoma. N. Engl.
J. Med., 311, 1471.
LEE, M.S., CHANG, K.S., CABANILLIS, F., FREIREICH, E.J., TRU-
JILLO, J.M. & STASS, S.A. (1987). Detection of minimal residual
cells carrying the t(14;18) by DNA sequence amplification.
Science, 237, 175.
LEMIRE, J.M., ADAMS, J.S., SAKAI, R. & JORDAN, S.C. (1984). 1,25-
dihydroxyvitamin D suppresses proliferation and immuno-
globulin production by normal human peripheral blood
mononuclear cells. J. Clin. Invest., 74, 657.
MANOLAGAS, S.C., PROWEDINI, D.M., MURRAY, E.J., MURRAY,
S.S., TSONIS, P.A. & SPANDIDOS, D.A. (1987). Association
between the expression of the c-myc oncogene mRNA and the
expression of the receptor protein for 1,25-dihydroxyvitamin D3.
Proc. Natl Acad. Sci. USA, 84, 856.
MILLER, A.B., HOOGOTRATEN, B., STEGNET, M. & WINKLER, A.
(1981). Reporting results of cancer treatment. Cancer, 47, 207.
PIKE, J.W. (1985). In Vitamin D: Chemical, Biochemical and Clinical
Update. Normal, A.W., Schaefer, K., Grigoleit, H.G. & VON
Herrath, D. (eds). de Gruyter: Berlin. 97.
PROVVEDINI, D.M., TSOUKAS, C.D., DEFTOS, L.J. & MANOLAGAS,
S.C. (1983). 1,25-hydroxyvitamin D3 receptors in human
leucocytes. Science, 221, 1181.
REITMAN, P.H., ROTHBERG, P.G., ASTERIN, S.M. & ? others (1983).
Regulation of myc gene expression in HL-60 leukaemia cells by a
vitamin D metabolite. Nature, 306, 492.
SCHEIN, P.S., CHABNER, R.A., CHANNELOS, G.P., YOUNG, R.C. &
DE VITA, V.T. (1975). Non-Hodgkin's lymphoma: patterns of
relapse from complete remission after combination
chemotherapy. Cancer, 35, 354.
TSOUKAS, C.D., PROVVEDINI, D.M. & MANOLAGAS, S.C. (1984).
1,25-dihydroxyvitamin D: a novel immunoregulatory hormone.
Science, 224, 1438.
WIERNIK, P.H. (1976). Spontaneous regression of haematologic
cancers. Natl Cancer Inst. Monogr., 44, 35.